Research institute
Galapagos NV will refocus its clinical pipeline and make some cost adjustments to save the company €150 million after disappointing studies assessing therapies for rheumatoid arthritis and idiopathic pulmonary fibrosis.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Since emerging from stealth mode in 2020 Dyno Therapeutics has been busy advancing its gene therapy platform. This morning, the company bolsters its research with $100 million raised in a Series A financing round.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 4, 2021.
As Tenaerts takes the scientific helm at Medable, she will leverage the company’s proprietary platform to advance decentralized research methodologies with evidence-based best practices for patient-centric clinical trials.
Researchers are continuing to develop next-generation therapeutics and oral vaccines that could overcome some vaccine hesitancy. Here are some of the top producers.
According to Teo, the definition of the next pandemic depends a lot on one’s perspective.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 27, 2021.
With the U.S. Food and Drug Administration’s vaccines advisory committee meeting being held today to discuss the Johnson & Johnson vaccine and blood clotting, there’s even more interest in what’s going on in the pandemic than usual. Here’s a look at some of the top stories.
A new study suggests that many patients with long-term COVID-19 symptoms still experience health issues six months following infection, are survivors with “long haul” disease have a greater risk of dying and use a more significant number of medications than patients who have fully recovered from the virus.
PRESS RELEASES